Abbott Laboratories (ABT) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Abbott Laboratories.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:01.954 Good morning and thank you for standing by. 00:00:01.954 -- 00:00:07.601 Welcome to Abbott's third quarter 2025 earnings conference call. 00:00:07.601 -- 00:00:11.367 All participants will be able to listen only until the question and answer portion of 00:00:11.367 -- 00:00:16.894 this call. During the question and answer session, you will be able to ask your question 00:00:16.894 -- 00:00:21.260 by pressing the star 1 1 keys on your touchtone phone. 00:00:21.260 -- 00:00:26.467 This call is being recorded by Abbott. With the exception of any participants questions 00:00:26.467 -- 00:00:31.033 asked during the question and answer session, the entire call including the question 00:00:31.033 -- 00:00:35.037 and answer session, is material copyrighted by Abbott. 00:00:35.037 -- 00:00:40.161 It cannot be recorded or rebroadcast without Abbott's express written permission. 00:00:40.161 -- 00:00:46.165 I would now like to introduce Mr. Mike Camilla, Vice President, Investor Relations. 00:00:46.267 -- 00:00:48.189 Good morning and thank you for joining us. 00:00:48.189 -- 00:00:53.874 With me today are Robert Ford, Chairman and Chief Executive Officer, and Phil Boudreau, 00:00:53.874 -- 00:00:58.587 Executive Vice President, Finance and Chief Financial Officer. 00:00:58.587 -- 00:01:01.353 Robert and Phil will provide opening remarks. 00:01:01.353 -- 00:01:04.721 Following their comments, we'll take your questions. 00:01:04.721 -- 00:01:09.331 Before we get started, some statements made today may be forward looking for purposes 00:01:09.331 -- 00:01:14.683 of the Private Securities Litigation Reform Act of 1995, including 00:01:14.683 -- 00:01:18.567 the expected financial results for 2025. 00:01:18.989 -- 00:01:23.875 Abbott cautions tha...